Exhibit 107
Calculation of Filing Fee Table
Form S-8
(Form Type)
BioMarin Pharmaceutical Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| Security Type | Security Class Title | Fee Calculation Rule | Amount Registered(1) | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | |||||||
| Equity | Common Stock | Other(2) | 14,000,000(3) | $81.09(2) | $1,135,260,000 | 0.0001476 | $167,564.38 | |||||||
| Total Offering Amounts | $1,135,260,000 | $167,564.38 | ||||||||||||
| Total Fees Previously Paid | — | |||||||||||||
| Total Fee Offsets | — | |||||||||||||
| Net Fee Due | $167,564.38 | |||||||||||||
| (1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock (“Common Stock”) of BioMarin Pharmaceutical Inc. (the “Registrant”) that become issuable under the Registrant’s 2017 Equity Incentive Plan, as Amended April 3, 2023 (the “2017 Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction effected that increases the number of outstanding shares of Common Stock. |
| (2) | Estimated in accordance with Rule 457(h) and Rule 457(c) under the Securities Act. The price per share and aggregate offering price are based upon the average of the high and low prices of the Registrant’s Common Stock on October 27, 2023 as reported on the Nasdaq Global Select Market. |
| (3) | Represents additional shares of the Registrant’s Common Stock reserved for future issuance under the Registrant’s 2017 Plan. |
